ACTU

ACTU

USD

Actuate Therapeutics Inc. Common stock

$6.590+0.090 (1.385%)

Prix en Temps Réel

Healthcare
Biotechnologie
États-Unis

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché
Fondamentaux de l'Entreprise
Statistiques de Trading

Métriques de Marché

Ouverture

$6.500

Haut

$6.660

Bas

$6.461

Volume

0.02M

Fondamentaux de l'Entreprise

Capitalisation Boursière

153.2M

Industrie

Biotechnologie

Pays

United States

Statistiques de Trading

Volume Moyen

0.07M

Bourse

NGM

Devise

USD

Intervalle sur 52 Semaines

Bas $5.47Actuel $6.590Haut $11.99

Actualités Connexes

Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $20 Price Target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics with a Buy and maintains $20 price target.

Voir plus
HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $20 Price Target
GlobeNewswire

Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months

Elraglusib represents a potential back bone therapy in pancreatic cancer with three ongoing trials in combination with current standards of care and novel immunotherapiesRecent financing provides extended runway through

Voir plus
Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months
GlobeNewswire

Actuate Therapeutics Announces Closing of $17.25 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option

CHICAGO and FORT WORTH, Texas, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for

Voir plus
Actuate Therapeutics Announces Closing of $17.25 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option
GlobeNewswire

Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock

CHICAGO and FORT WORTH, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for

Voir plus
Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock
GlobeNewswire

Actuate Therapeutics Announces Proposed Public Offering of Common Stock

CHICAGO and FORT WORTH, Texas, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for

Voir plus
Actuate Therapeutics Announces Proposed Public Offering of Common Stock

Restez Informé

Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.